相关临床试验
11
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
54.5%
尚未招募
4
36.4%
招募中
1
9.1%
暂无批准数据
- The HyPrevent platform has assembled a deeply phenotyped longitudinal cohort of over 3,600 participants to study how hypertension during pregnancy affects the heart, brain, and blood vessels across the life course. - Researchers developed a unified global organ-damage risk score (HyperScore) and identified distinct disease progression pathways (HyperTrajectories) linked to mortality and advanced organ damage. - The Lapidaire Group investigates postpartum brain and microvascular changes using multimodal imaging and a novel portable device (VITA) to detect early cerebrovascular and microvascular alterations. - Findings aim to inform better prevention and management strategies, with integration into a clinical postnatal hypertension service and the ongoing FLOWER study at Oxford University Hospitals.
- The NHS has launched GlobalMinds, the world's largest mental health study, recruiting 49,000 participants with severe mental illness including schizophrenia, bipolar disorder, and major depression to develop personalized treatments. - The three-year study combines genetic data from blood or saliva samples with questionnaire responses and NHS medical records to create the most detailed dataset on serious mental health conditions. - Researchers aim to transform understanding of severe mental illness and unlock precision medicine approaches similar to those that have revolutionized cancer treatment. - The study is supported by 10 NHS trusts and led by Akrivia Health in partnership with Cardiff University, with funding from the Wellcome Trust and Johnson & Johnson.
- Australian biotech company Vaxxas has received a TGA manufacturing license for its high-density microarray patch (HD-MAP) technology, enabling GMP production for clinical trials. - The HD-MAP technology has demonstrated safety and tolerability in over 750 participants across six first-in-human trials, showing equal or greater immune responses at lower doses. - The patch-based vaccine delivery system reduces cold-chain requirements and enables self-administration, potentially transforming global vaccine access and distribution. - Vaxxas has completed trials for COVID-19, influenza, measles, and rubella vaccines with support from partners including SK bioscience and the Gates Foundation.
- University College London researchers have successfully engineered rare γδT cells with stabilized interleukin-15 and B7-H3 antibodies to target slow-growing bowel cancer cells that resist conventional chemotherapy. - The engineered cells demonstrated dual cytotoxic mechanisms (AIC and ADCC) that prevented tumor-mediated immune evasion and maintained robust killing activity across over 1,000 experimental conditions using patient-derived organoids. - This breakthrough addresses a critical clinical challenge, as bowel cancer claims over 900,000 lives annually worldwide, with slow-cycling cancer cells often surviving chemotherapy and causing aggressive relapses. - The γδT cells' allogeneic transfer capability could enable donor-derived therapies, potentially overcoming manufacturing obstacles that limit widespread accessibility of personalized T cell treatments.
- The Union Cabinet has approved the third phase of India's Biomedical Research Career Programme (BRCP) with a total investment of ₹1,500 crore from 2025-26 to 2030-31, funded jointly by India's Department of Biotechnology (₹1,000 crore) and the UK's Wellcome Trust (₹500 crore). - The programme aims to train over 2,000 students and postdoctoral fellows while expanding biomedical research capacity into tier-2 and tier-3 cities to reduce regional disparities in scientific infrastructure. - Phase III will focus on developing translational biomedical innovation through early career fellowships, collaborative grants, and research management programmes, with goals to increase women's participation by 10-15% and enable 25-30% of collaborative programmes to reach Technology Readiness Level 4 or higher.
- Medicines Discovery Catapult has formed two major strategic partnerships with the Francis Crick Institute and University of Exeter to accelerate drug discovery and translational research across the UK. - The partnership with the Francis Crick Institute will support KQ Labs, a national accelerator that has helped 70 start-ups raise over £219 million in investment since 2018. - The University of Exeter collaboration aims to bridge the gap between academic research and industrial drug development by providing industry-standard validation and translational support. - These partnerships represent a new blueprint for academic-industry collaboration designed to maximize the impact of UK biomedical research and enhance the nation's life sciences ecosystem.
- The UK government has announced a £600 million ($764m) investment to create a Health Data Research Service, providing researchers with a single, secure access point to national health datasets. - The initiative aims to reduce clinical trial setup times from over 250 days to 150 days by March 2026 through streamlining bureaucracy and standardizing contracts. - Pharmaceutical industry leaders, including GSK CEO Emma Walmsley, have welcomed the investment, highlighting the UK's unique potential to leverage NHS data to accelerate medical innovation.
- Researchers found that carbonic anhydrase (CA) inhibitors, particularly methazolamide, significantly reduced tau protein levels in animal models. - The study used zebrafish and mouse models genetically engineered to express human tau protein, showing improved neuronal health and cognitive performance with methazolamide. - The findings suggest CA inhibitors could slow neurodegeneration by accelerating tau clearance, potentially benefiting diseases like Alzheimer’s. - Further studies are needed to assess long-term effects and optimal dosage in humans, despite the promising results in animal models.
- Bill Gates expressed optimism about the M72 tuberculosis vaccine clinical trial, anticipating a 70% efficacy in reducing the disease. - The ongoing Phase 3 trial, costing $500 million, is a collaboration between GSK, the Wellcome Trust, and the Gates MRI. - The M72/AS01E vaccine aims to prevent pulmonary TB in adolescents and adults, potentially marking the first new TB vaccine in over a century. - Current TB treatments require a nine-month regimen, and multidrug-resistant TB remains a significant public health challenge, spurring the need for new drugs and vaccines.
- Major UK medical research funders allocate less than 1% of their budgets to rare disease research, despite these conditions consuming 10% of the NHS specialized services budget. - Research into rare diseases like alkaptonuria (AKU) has proven valuable for understanding common conditions such as osteoarthritis, demonstrating their broader scientific importance. - Public awareness initiatives like the French Telethon, which raised €94 million in 2011, show the potential for increased rare disease funding through effective advocacy campaigns.
